How to Sequence Anabolics/Antiresorptives
Includes a Live Web Event on 04/12/2026 at 11:00 AM (EDT)
How to Sequence Anabolics/Antiresorptives
Sabashini Ramchand, MBBS
Sunday, April 12, 2026, 11:00am to 11:45am Eastern Time (NY/USA)
Description and Objectives
Interactive session on the topic of optimizing the sequence of osteoporosis therapies for maximum benefit.
After this session, participants should be able to:
- Evaluate the clinical evidence supporting the initiation of treatment with osteo-anabolic drugs rather than anti-resorptive drugs for patients at very high or imminent risk of fracture.
- Identify the pharmacological "off-sets" of different osteoporosis therapies.
- Implement effective transition protocols when moving from one therapy class to another, with a specific focus on the mandatory follow-up for denosumab and anabolic therapies.
Sabashini Ramchand, MBBS
Staff Endocrinologist
Cleveland Clinic
Dr. Sabashini Ramchand is a Staff Endocrinologist at the Cleveland Clinic and an Assistant Professor at the Lerner College of Medicine – Case Western Reserve University. As a clinician-researcher, she is an emerging leader in the field of metabolic bone disease, notably serving as the Clinical Co-Chair for the ASBMR 2023 Annual Meeting. Her primary research and clinical interests involve the optimization of medical therapies for osteoporosis, including the strategic use of combination and sequential treatment regimens, as well as the optimization of skeletal health in patients experiencing bone loss due to breast cancer treatments. Dr. Ramchand completed her medical training and endocrine fellowship in Melbourne, Australia, and then transitioned to a research fellowship at Massachusetts General Hospital, Harvard Medical School before she joined the Cleveland Clinic in 2024.